13 results about "MMP2" patented technology

The invention discloses an oligonucleotide intracellular nano delivery system based on polypeptide modification and application thereof. The system is composed of a periostin targeting sequence (SDSSD), a matrix metalloproteinase 2 (MMP2) response sequence (GPAGLLG), a cell penetrating sequence (RRRRRRRR, R9), a reactive oxygen species (ROS) scavenging and adhesion enhancing group (Gly-DOPA)) and a terminal dibenzocyclooctyne (DBCO) modified engineered polypeptide SDSSD-PEG5-YGFGG-GPAGLLG-R9-(G-DOPA) 3-K4-C-DBCO, and a target oligonucleotide miRNA-26a-A5-Azido modified by 5-polyadenylic acid (AAAAA) and an azide group (Azido), and the target oligonucleotide miRNA-26a-A5-Azido, the target oligonucleotide and assembling through a click chemical reaction and a non-covalent interaction. The nano system has good bone targeting, enzyme responsiveness, intracellular delivery effect and biological safety, can realize stable and efficient delivery of therapeutic oligonucleotides in vivo, and significantly improves the utilization efficiency and therapeutic potential of oligonucleotides. The oligonucleotide intracellular nano delivery system has a wide application prospect in the fields of clinical transformation and precise treatment of oligonucleotide drugs.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

The invention provides application of a bisindole compound XQ-016 in treatment of osteosarcoma, and belongs to the technical field of biological medicines. The bisindole compound XQ-016 can inhibit proliferation, migration and invasion of tumor cells by adjusting an STAT3 / p53 signal channel, inducing G1 phase cell cycle arrest and inhibiting MMP2 / MMP9 expression, shows remarkable anti-tumor activity, is a promising treatment choice in tumor treatment, and can be used as an effective component in anti-tumor drugs.

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The invention discloses an osteonecrosis early diagnosis kit based on blood detection and a biomarker, and the osteonecrosis early diagnosis kit can be used for early diagnosis of osteonecrosis through multi-omics screening based on femoral head necrosis lesion division, serological analysis of different stages of cases and cell and animal level biological tests in combination with actual detection result verification. It is determined that a group of biomolecules, namely PEBP1, ACAT1, MMP2, SOD1 and FN1 proteins, can be used for early diagnosis of osteonecrosis.

This invention provides the use of Cm-CATH2 in the preparation of drugs for treating silicosis, belonging to the field of biomedical technology. This invention provides the application of Cm-CATH2 and / or pharmaceutically acceptable salts of Cm-CATH2 in the preparation of drugs for treating silicosis, and verifies the therapeutic effect of Cm-CATH2 on silicosis animal models by constructing such models. The results show that Cm-CATH2 can act on silicosis at multiple targets after the early stage of silicosis in animal models. It reduces oxidative stress levels by downregulating lactate dehydrogenase (LDH), downregulates matrix metalloproteinase 2 (MMP2) and extracellular matrix glycosaminoglycans (GAG), and ultimately reduces collagen III (COL-III) levels, thereby achieving an anti-fibrotic effect. This multi-target approach can effectively alleviate fibrosis progression. Therefore, Cm-CATH2 can be used to treat silicosis, and a dose-response effect exists, with good efficacy at high doses.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.

The invention discloses a matrix metalloproteinase MMP2 gene and application of dsRNA of the matrix metalloproteinase MMP2 gene in prevention and treatment of ladybird beetles. The dsRNA for synthesizing the matrix metalloproteinase gene MMP2 of the ladybird is injected into the body of the ladybird, so that the MMP2 gene of the ladybird can be specifically silenced, the ecdysis of the larva of the ladybird can be inhibited, the metamorphosis and development of the larva fail, then the individual death is caused, and the purpose of biological control is achieved; the method has the advantages of specificity, high efficiency and environmental protection in pest control, is a novel green pollution-free ladybird prevention and control technology, and shows a huge application prospect in prevention and control of ladybird.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a low stromal gene signature score. In some aspects, the low stromal gene signature score is determined by measuring the expression of a panel of stromal genes in a tumor sample obtained from the subject, wherein the stromal gene panel comprises at least four genes selected from CDH1, CDH2, MMP1, MMP2, ITGA1, ITGA2, ITGA3, ITGA5, ITGA7, ITGA11, TGFB1, and TGFB1; at least four genes selected from TGFB1, TGFBR2, ACTA2, COL4A1, TAGLN, SH3PXD2A, TWIST1, ZEB1, and ZEB2; or MMP2 and MMP9.

This invention relates to a drug molecule that inhibits collagen fiber formation and its application. The drug molecule comprises a hydrophilic unit, a lysyl oxidase inhibitory unit, a matrix metalloproteinase 2 (MMP2) responsive peptide, a collagen self-assembly interfering peptide, and a hydrophobic unit connected in sequence. The drug molecule contains two main active ingredients: a lysyl oxidase inhibitory unit that inhibits lysyl oxidase activity during collagen cross-linking, and a collagen self-assembly interfering peptide that inhibits collagen self-assembly. These two components can inhibit the covalent cross-linking process of collagen from multiple perspectives, reducing collagen fiber formation. Simultaneously, the MMP2 responsive peptide in the drug molecule responds to MMP2, causing the drug molecule to disintegrate and releasing the two main active ingredients. This inhibits excessive collagen deposition at wound sites and promotes collagen remodeling at skin wound sites towards characteristics closer to normal skin collagen.

The invention discloses application of CD44v9 positive M2 type macrophages in preparation of gastric adenocarcinoma diagnosis or treatment products, in the technical scheme provided by the invention, it is proved that the M2 type macrophages of CD68 + CD86-CD163 + can express CD44v9 through multiple fluorescent staining, human acute mononuclear leukemia cells (THP-1 cells) are subjected to in-vitro culture and are sequentially induced into M0 type macrophages and M2 type macrophages, and the M0 type macrophages and the M2 type macrophages can be used for diagnosing or treating gastric adenocarcinoma. Then, the expression conditions of the M0 type macrophage CD44v9 and the M2 type macrophage CD44v9 are observed, and the result shows that the M0 type macrophage and the M2 type macrophage which are induced by the THP-1 cell in vitro can express the CD44v9, and the expression level of the M2 type macrophage is higher than that of the M0 type macrophage CD44v9. Afterwards, after co-culture with gastric adenocarcinoma AGS cells in M2 macrophages infected and induced by over-expressed CD44v9 lentivirus, the proliferation, migration and invasion capabilities of the AGS cells are enhanced, and the epithelial-mesenchymal transition of the AGS cells and the expression of matrix metalloproteinases (MMP2 and MMP9) are promoted.

The invention discloses a chimonanthus salicifolius extract and a preparation method and application thereof, and belongs to the technical field of medicines.The preparation method comprises the steps that dry chimonanthus salicifolius leaves are subjected to reflux extraction through an ethanol water solution, an ethyl acetate part is obtained through extraction, and then separation and purification are conducted through a silica gel column, gel column chromatography, a reversed-phase C18 column and semi-preparative high performance liquid chromatography in sequence to obtain the chimonanthus salicifolius extract. The high-purity target compound 1 and the high-purity target compound 2 are obtained. Compared with the prior art, an in-vitro cell experiment shows that the compound 1 and the compound 2 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M, the secretion levels of tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-2 (MMP2) can be reduced, the compound 1 can also inhibit the secretion of interleukin-2 (IL-2), and the compound 2 and the compound 1 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M; safe and effective natural medicine candidate molecules are provided for gastrointestinal inflammation diseases such as functional dyspepsia, and the good clinical transformation potential is achieved.

The present invention relates to an anti-fibrotic composition for preventing or treating fatty liver or liver cirrhosis, the composition containing jujube polysaccharides as an active ingredient. The jujube polysaccharide-containing composition according to the present invention can significantly inhibit the expression of fibrosis-related mRNAs (Tgf-β, Col1a1, Col4a1, Pdgfb, Mmp1, Mmp2, and Timp1) induced in LX2 hepatic stellate cells by TGF-β1, and the whole-cell expression and nucleus expression of fibrosis-related proteins (p-SMAD2, SMAD2, p-SMAD3, SMAD3, and SMAD4). In addition, the jujube polysaccharide-containing composition can significantly suppress body fat mass (fat mass (g), adiposity (% fat)) increased by a high-fat, high-fructose diet (HFHFD), and significantly reduce hepatic steatosis and inflammation. Therefore, the jujube polysaccharide-containing composition according to the present invention is expected to be advantageously used as an anti-fibrotic composition for preventing, alleviating, and treating fatty liver or liver cirrhosis.